GPP 是一種罕見的、復發性或持續發作的嚴重皮膚疾病^{[1],[2]<\/sup>，臨床上與斑塊狀銀屑病不同^{[4],[5]<\/sup>。GPP是由中性粒細胞（一種白細胞）在皮膚中積聚引起的，會在全身廣泛爆發疼痛性的無菌性膿皰^{[4],[5]<\/sup>。GPP患者的臨床病程各不相同，有些患者可反復發作，而另一些患者則表現為疾病持續存在且間歇性發作^{[4]<\/sup>。雖然GPP發作的嚴重程度各不相同，但若不及時治療，可能會出現敗血癥和多系統器官衰竭等并發癥，可能會危及生命^{[5]<\/sup>。這種慢性全身性疾病會對患者的生活質量產生重大影響，并增加醫療負擔^{[11]<\/sup>。GPP在不同區域的患病率各不相同，女性患者多于男性患者^{[5],[11],[12],[13],[14]<\/sup>。對于能夠快速解決GPP發作癥狀并能減少復發，且具有可接受的安全性的療法存在著高度未滿足的需求^{[2],[6]<\/sup>。GPP的發作可導致住院并可能發生嚴重并發癥，包括心力衰竭、腎衰竭和敗血癥，而疾病發作的不可預測性和嚴重程度極大地影響了患者的生活質量^{[5],[6]<\/sup>。<\/p> \n}}}}}}}}}

圣利卓^{®<\/sup><\/b>家族（通用名：佩索利單抗）包含靜脈注射制劑和皮下注射制劑，是一款新型人源化選擇性抗體，可阻斷白介素-36受體 (IL-36R)的激活。IL-36通路是免疫系統內的一種信號通路，已被證明與GPP等多種自身炎癥性疾病的發病機制有關^{[5],[7],[8]<\/sup>。佩索利單抗靜脈注射制劑已獲得包括美國、日本、中國和歐盟等多國監管機構批準，用于治療成人GPP發作。<\/p> \n}}

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
<optgroup id="kgssg"></optgroup>
<center id="kgssg"></center>
久久久亚洲欧洲日产国码二区
[1] Lebwohl M et al. Spesolimab for the prevention of generalized pustular psoriasis (GPP) flares: Results from the randomized, placebo-controlled trial Effisayil 2. Abstract presented at the 25th World Congress of Dermatology July 2023, Singapore.<\/span><\/p> <\/td> \n <\/tr> \n
[2] Kharawala S, et al. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review. Exp Rev Clin Immunol. 2020;16(3):239-252.<\/span><\/p> <\/td> \n <\/tr> \n
[3] Bachelez, H. Pustular psoriasis: the dawn of a new era. Acta Derm Venereol. 2020;100(3):adv000343<\/span><\/p> <\/td> \n <\/tr> \n
[4] 《我國泛發性膿皰型銀屑病的患病率和疾病負擔調查：一項基于全國2012-2016年城鎮醫療保險數據的估算》，中華醫學會第二十七次全國皮膚性病學學術年會，2021年6月<\/span><\/p> <\/td> \n <\/tr> \n
[5] Navarini AA, et al. European consensus statement on phenotypes of pustular psoriasis. JEADV. 2017;31:1792-1799.<\/span><\/p> <\/td> \n <\/tr> \n
[6] Crowley JJ, et al. A brief guide to pustular psoriasis for primary care providers, Postgraduate Medicine. 2021;133(3):330-344.<\/span><\/p> <\/td> \n <\/tr> \n
[7] Puig L, Choon SE, Gottlieb AB, et al. Generalized pustular psoriasis: a global Delphi consensus on clinical course, diagnosis, treatment goals, and disease management. J Eur Acad Dermatol Venereol. 2023 Jan 6. doi: 10.1111\/jdv.18851.<\/span><\/p> <\/td> \n <\/tr> \n
[8] Furue K, et al. Highlighting Interleukin-36 Signalling in plaque psoriasis and pustular psoriasis. Acta Derm Venereol. 2018;98:5–13.<\/span><\/p> <\/td> \n <\/tr> \n
[9] Bachelez H, et al. Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis. N Engl J Med. 2019; 380:981-983.<\/span><\/p> <\/td> \n <\/tr> \n
[10] Lebwohl M et al. Spesolimab for the prevention of generalized pustular psoriasis (GPP) flares: Results from the randomized, placebo-controlled trial Effisayil 2. Abstract presented at the 25th World Congress of Dermatology July 2023, Singapore.<\/span><\/p> <\/td> \n <\/tr> \n
[11] Hanna M, et al. Economic burden of generalized pustular psoriasis and palmoplantar pustulosis in the United States. Curr Med Res Opin. 2021. 37(5):735-742.<\/span><\/p> <\/td> \n <\/tr> \n
[12] Augey F, et al. Generalized pustular psoriasis (Zumbusch): a French epidemiological survey. Eur J Derm. 2006; 16(6):669-673.<\/span><\/p> <\/td> \n <\/tr> \n
[13] Ohkawara A et al. Generalized pustular psoriasis in Japan: two distinct groups formed by differences in symptoms and genetic background. Acta Derm Venereol. 1996 Jan;76(1):68–71.<\/span><\/p> <\/td> \n <\/tr> \n
[14] Jin H, et al. Clinical features and course of generalized pustular psoriasis in Korea. J Dermatol. 2015; 42(7):674-678.<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n
<\/p>"]; $("#dvExtra").html(content_array[0]);})();
<center id="kgssg"></center>